Top Abstract Purchase Related
Home
>
Node
>
Subnode

Toxicity and antitumor activity of niosomal bleomycin in tumor bearing mice

Naresh, R.A.; Udupa, N.; Devi, P.U.

Indian Journal of Experimental Biology 34(8): 764-772

1996

ISSN/ISBN: 0019-5189
PMID: 8979482
Document Number: 464761
Niosomal encapsulation of bleomycin enhanced the antitumor activity against Ehrilich ascites and sarcoma-180 models. The niosomal/free drug mean survival time values of 1.28 was achieved in Ehrlich ascites infected animals. Niosomal bleomycin considerably increased the 40 days survival rate in mice. Tumor volume doubling time of S-180 tumor was also increased significantly in niosomal treated animals. Histopathological studies of lung and jejunum of Niosomal bleomycin treated mice, confirmed the less toxic potential of encapsulated bleomycin. The suppression of peripheral and bone marrow WBC counts upon niosomal bleomycin treatment was not substantial.

Document emailed within 1 workday
Secure & encrypted payments

Viale, M.; Vánnozzi, M.O.; Mandys, V.; Esposito, M. 2001: Time-dependent influence of procaine hydrochloride on cisplatin antitumor activity in P388 tumor bearing mice Anticancer Research 21(1a): 485-487
Fuyama, S.; Yamamoto, H.; Arai, S. 1985: Characterization of effector cells mediating antitumor activity in spleen cells of tumor-bearing mice Cancer Research 45(9): 4103-4108
Eastland, G.W.; Yang, G.; Thompson, T. 1983: Studies of rhenium carboxylates as antitumor agents. Part II. Antitumor studies of bis (mu-propionato) diaquotetrabromodirhenium (III) in tumor-bearing mice Methods and Findings in Experimental and Clinical Pharmacology 5(7): 435-438
Warren, P.; Song, W.; Holle, E.; Holmes, L.; Wei, Y.; Li, J.; Wagner, T.; Yu, X. 2002: Combined HSV-TK/GCV and secondary lymphoid tissue chemokine gene therapy inhibits tumor growth and elicits potent antitumor CTL response in tumor-bearing mice Anticancer Research 22(2a): 599-604
Tzai, T.S.; Shiau, A.L.; Liu, L.L.; Wu, C.L. 2000: Immunization with TGF-beta antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of MBT-2 tumor-bearing mice through upregulation of MHC class i and Fas expressions Anticancer Research 20(3a): 1557-1562
Lupatov, A.I.; Brondz, B.D. 1992: T-suppressors from tumor-bearing mice inhibit antitumor cytotoxic T-lymphocytes in monoculture Biulleten' Eksperimental'noi Biologii i Meditsiny 113(2): 186-187
Cao, S.; Troutt, A.B.; Rustum, Y.M. 1998: Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer Cancer Research 58(8): 1695-1699
Akimoto, M.; Ohuchi, N.; Matano, S.; Hirakawa, H.; Abe, M.; Nishihira, T.; Mori, S. 1989: Reduction of 5-FU toxicity with improved nutritional status in tumor bearing mice Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(11): 3609-3613
Takahashi, M. 1991: Specific antitumor effect of lymphokine-activated lymphocytes obtained from tumor-bearing mice after intratumoral injection of interleukin-2 (IL-2) Nihon Geka Gakkai Zasshi 92(3): 247-256
Kato, T.; Suzumura, Y.; Takamoto, S.; Ota, K. 1987: Antitumor activity and toxicity in mice of RA-700, a cyclic hexapeptide Anticancer Research 7(3 Part B): 329-334
Lake, L.M.; Grunden, E.E.; Johnson, B.M. 1975: Toxicity and antitumor activity of hexamethylmelamine and its N-demethylated metabolites in mice with transplantable tumors Cancer Research 35(10): 2858-2863
Farrar, W.L.; Elgert, K.D.; Foo, A.S. 1981: Suppressor cell activity in tumor-bearing mice. III. Co-purification of a factor inhibiting cellular DNA synthesis and DNA polymerase activity Journal of Immunology 127(6): 2339-2344
Kreitman, R.J.; Puri, R.K.; Pastan, I. 1995: Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma Cancer Research 55(15): 3357-3363
Zou, J.P.; Shimizu, J.; Ikegame, K.; Yamamoto, N.; Ono, S.; Fujiwara, H.; Hamaoka, T. 1992: Tumor-bearing mice exhibit a progressive increase in tumor antigen-presenting cell function and a reciprocal decrease in tumor antigen-responsive CD4+ T cell activity Journal of Immunology 148(2): 648-655
Tanaka, K.; Koga, Y.; Taniguchi, K.; Nomoto, K. 1987: T-cell recruitment from the thymus to the spleen in tumor bearing mice: phenotypical alteration and recruitment of thymocytes raised in a tumor bearing state Cancer Research 47(8): 2136-2141
Zhang, J.P.; Qian, D.H. 1993: Antitumor activity and tumor necrosis factor production of Phytolacca acinosa polysaccharides I in mice Zhongguo Yao Li Xue Bao 14(6): 542-545
Futami, H.; Jansen, R.; MacPhee, M.J.; Keller, J.; McCormick, K.; Longo, D.L.; Oppenheim, J.J.; Ruscetti, F.W.; Wiltrout, R.H. 1990: Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy Journal of Immunology 145(12): 4121-4130
Elgert, K.D.; Farrar, W.L. 1978: Suppressor cell activity in tumor-bearing mice. I. Dualistic inhibition by suppressor T lymphocytes and macrophages Journal of Immunology 120(4): 1345-1353
Kaneda, Y.; Yamamoto, Y.; Kamada, H.; Tsunoda, S.; Tsutsumi, Y.; Hirano, T.; Mayumi, T. 1998: Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice Cancer Research 58(2): 290-295
Chen, G.; Pan, Q.C. 1985: Enhancement of the antitumor activity of bleomycin A5 by 3-aminobenzamide in vitro and in vivo Yao Xue Xue Bao 20(5): 331-333